However, our proportion was derived from population-based rather than clinic-based data, the first DMD (interferon beta-1b) was only approved for use in Canada in 1995, and not all individuals with MS would have been eligible for treatment (including those unable to walk, those without relapses and those with a primary progressive disease course). This evidence concerns the gene DMD and myeloid sarcoma.